Axatilimab Proves Highly Effective in Recurrent/Refractory Chronic GVHD

Axatilimab can produce durable responses in patients with recurrent or refractory chronic GVHD, a phase 2 trial suggests.

Related Keywords

Germany ,Daniel Wolff ,University Hospital Regensburg ,Organ System With ,